False-positive screening results in the European randomized study of screening for prostate cancer

European Journal of Cancer

Volumn 47, Issue 18, 2011, Pages 2698-2705

  Kilpeläinen, Tuomas P ^a,b   Tammela, Teuvo L J ^a   Roobol, Monique ^c   Hugosson, Jonas ^d   Ciatto, Stefano ^e   Nelen, Vera ^f   Moss, Sue ^g   Määttänen, Liisa ^h   Auvinen, Anssi ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ISPO   (Italy)

^f Provinciaal Instituut voor Hygiene   (Belgium)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h FINNISH CANCER REGISTRY   (Finland)

Author keywords

Mass screening; Prostatic neoplasms; PSA; Randomized controlled trials; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

AGED; FALSE POSITIVE REACTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 82255186335     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.055     Document Type: Article

References (31)

1. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. G. Draisma, R. Etzioni, and A. Tsodikov Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J Natl Cancer Inst 101 2009 374 383
3. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990 (Pubitemid 34814727)
4. L. Määttänen, M. Hakama, and T.L.J. Tammela Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial Br J Cancer 96 2007 56 60 (Pubitemid 46094639)
5. T.P. Kilpeläinen, T.L. Tammela, and L. Määttänen False-positive screening results in the Finnish prostate cancer screening trial Br J Cancer 102 2010 469 474
6. J.M. Croswell, B.S. Kramer, and A.R. Kreimer Cumulative incidence of false-positive results in repeated, multimodal cancer screening Ann Fam Med 7 2009 212 222
7. V. Nelen, G. Thys, and H. Neels ERSPC: features and preliminary results from the Antwerp study centre BJU Int 92 Suppl. 2 2003 17 21 (Pubitemid 38091133)
8. T. Mäkinen, T.L. Tammela, and U.H. Stenman Second round results of the Finnish population-based prostate cancer screening trial Clin Cancer Res 10 2004 2231 2236 (Pubitemid 38445679)
9. S. Ciatto, G. Gervasi, and P. Frullini Specific features of the Italian section of the ERSPC BJU Int 92 Suppl. 2 2003 30 32 (Pubitemid 38091136)
10. M.J. Roobol, A. Grenabo, and F.H. Schröder Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam J Natl Cancer Inst 99 2007 1296 1303 (Pubitemid 47398681)
11. M.J. Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
12. T. Mäkinen, A. Auvinen, and M. Hakama Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study Urology 60 2002 846 850 (Pubitemid 35300352)
13. Carlsson S, Holmberg E, Moss S, et al. No excess mortality after prostate biopsy - Results from the European Randomized Study of Screening for Prostate Cancer (ERSPC). BJU Int [Epub 2010, Oct 15].
14. F.J. Fowler Jr. , M.J. Barry, and B. Walker-Corkery The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral and medical care outcomes J Gen Intern Med 21 2006 715 721 (Pubitemid 43973556)
15. J. Lafata, J. Simpkins, and L. Lamerato The economic impact of false-positive cancer screens Cancer Epidemiol Biomarkers Prev 13 2004 2126 2132 (Pubitemid 40054307)
16. P. Finne, A. Auvinen, and L. Määttänen Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg per liter Eur Urol 54 2008 362 370 (Pubitemid 351885247)
17. P. Finne, R. Finne, and C. Bangma Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening Int J Cancer 111 2004 310 315 (Pubitemid 38924712)
18. F.H. Schröder, M.J. Roobol, and T.H. van der Kwast Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49 2006 460 465 (Pubitemid 43259552)
19. R.D. Etzioni, D.P. Ankerst, and N.S. Weiss Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence J Natl Cancer Inst 99 2007 1510 1515 (Pubitemid 351767238)
20. C.H. Bangma, R.H. van Schaik, and B.G. Blijenberg On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer Eur J Cancer 46 2010 3109 3119
21. A. Gupta, M.J. Roobol, and C.J. Savage A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands Br J Cancer 103 2010 708 714
22. F.H. Jansen, R.H. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
23. A. Mehik, P. Hellström, and O. Lukkarinen Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study BJU Int 86 2000 443 448
24. T. Rhodes, C.J. Girman, and S.J. Jacobsen Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old J Urol 161 1999 1174 1179 (Pubitemid 29426112)
25. E.J. Wright, J. Fang, and E.J. Metter Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging J Urol 167 2002 2484 2487 (Pubitemid 34533151)
26. V. Nelen, G. Thys, and A. Hermans Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval Eur J Cancer 46 2010 3090 3094
27. A. Auvinen, J. Raitanen, and S. Moss Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands Cancer Epidemiol Biomarkers Prev 18 2009 2000 2005
28. P. Finne, M. Fallah, and M. Hakama Lead-time in the European randomised study of screening for prostate cancer Eur J Cancer 46 2010 3102 3108
29. M.E. Ford, S.L. Havstad, and R. Demers Effects of false positive prostate cancer screening results on subsequent prostate cancer screening behavior Cancer Epidemiol Biomarkers Prev 14 2005 190 194 (Pubitemid 40165302)
30. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
31. S.J. Otto, S.M. Moss, and L. Määttänen PSA levels and cancer detection rate by centre in the European randomized study of screening for prostate cancer Eur J Cancer 46 2010 3053 3060